Publications by authors named "Roman Weger"

Claim this Profile
A
Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study.
Jens Lehmann, Kelly M de Ligt, Stefanie Tipelius, Johannes M Giesinger, Monika Sztankay, Roman Weger

J Med Internet Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR).
Magdalena A Benda, Hanno Ulmer, Roman Weger, Patrick Reimann, Theresia Lang

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cancer patient's perspective of COVID-19-induced distress-A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic.
Karin A Koinig, Christoph Arnold, Jens Lehmann, Johannes Giesinger, Stefan Köck, Roman Weger

Cancer Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal.
Jens Lehmann, Petra Buhl, Johannes M Giesinger, Lisa M Wintner, Monika Sztankay, Roman Weger

J Med Internet Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.
Maurus Locher, Michael Steurer, Emina Jukic, Markus A Keller, Friedrich Fresser, Roman Weger

Am J Hematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Ella Willenbacher, Wolfgang Willenbacher, Roman Weger, Wolf Dominik, Claudia Manzl

Ann Hematol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complementing clinical cancer registry data with patient reported outcomes: A feasibility study on routine electronic patient-reported outcome assessment for the Austrian Myelome Registry.
Monika Sztankay, Lucia Neppl, Lisa M Wintner, Fanny L Loth, Wolfgang Willenbacher, Roman Weger

Eur J Cancer Care (Engl)· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
Marlies Antlanger, Tobias Dust, Thomas Reiter, Alexandra Böhm, Wolfgang W Lamm, Roman Weger

BMC Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma--an analysis from the Austrian Myeloma Registry.
Wolfgang Willenbacher, Ella Willenbacher, Claudia Zelle-Rieser, Rainer Biedermann, Roman Weger

Leuk Lymphoma· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR).
Wolfgang Willenbacher, Shanmugapriya Thangavadivel, Richard Greil, Ella Willenbacher, Roman Weger

Leuk Lymphoma· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Ella Willenbacher, Roman Weger, Ursula Rochau, Uwe Siebert, Wolfgang Willenbacher

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis